A randomized controlled trial of a weekly schedule of five consecutive days on treatment with efavirenz, tenofovir, and emtricitabine followed by two days off treatment (5/2 intermittent treatment schedule) versus continuous treatment in individuals with virologic suppression on this combination.

Trial Profile

A randomized controlled trial of a weekly schedule of five consecutive days on treatment with efavirenz, tenofovir, and emtricitabine followed by two days off treatment (5/2 intermittent treatment schedule) versus continuous treatment in individuals with virologic suppression on this combination.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2012

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms FOTO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Actual initiation date (Aug 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top